CompletedPhase 3NCT00782340
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Studying Dopamine beta-hydroxylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chelsea Therapeutics
- Principal Investigator
- Stephen Greer, MDArkansas Cardiology
- Intervention
- Placebo(drug)
- Enrollment
- 263 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2010
Study locations (21)
- North Alabama Neuroscience, Huntsville, Alabama, United States
- Mayo Clinic-Arizona, Scottsdale, Arizona, United States
- Arkansas Cardiology, Little Rock, Arkansas, United States
- University of California, Irvine, Irvine, California, United States
- Bradenton Neurology, Inc, Bradenton, Florida, United States
- Suncoast Neuroscience Associates, Inc, St. Petersburg, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Cncs, Ninds,Nih, Bethesda, Maryland, United States
- Nerological Reserch Center at Hattiesburg, Hattiesburg, Mississippi, United States
- North Shore Hospital, Manshasette, New York, United States
- Pennsylvania Hospital of the University of PA Health System- Department of Neurology, Philadelphia, Pennsylvania, United States
- HAN Neurological Associates, Upland, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
- Evergreen Hospital Medical Center; Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States
- University of Calgary, Calgary, Alberta, Canada
- +6 more locations on ClinicalTrials.gov
Collaborators
Chiltern International Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00782340 on ClinicalTrials.gov